Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Fox

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Neurology|April 18, 2020
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFITMarianna Cortese, Kassandra L Munger, Elena H Martínez-Lapiscina, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference ProceedingsChristopher M Perrone, Robert P Lisak, Ethan I Meltzer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 7, 2024
Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluidAleksandra M Wojtas, Eric B Dammer, Qi Guo, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
Proteomic Changes in the Human Cerebrovasculature in Alzheimer's Disease and Related Tauopathies Linked to Peripheral Biomarkers in Plasma and Cerebrospinal FluidAleksandra M Wojtas, Eric B Dammer, Qi Guo, et al.
Nature Communications|August 16, 2023
Whole genome deconvolution unveils Alzheimer's resilient epigenetic signatureEloise Berson, Anjali Sreenivas, Thanaphong Phongpreecha, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapyEva Havrdova, Douglas L Arnold, Jeffrey A Cohen, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialJeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, et al.
Scientific Reports|August 24, 2023
Cross-species comparative analysis of single presynapsesEloïse Berson, Chandresh R Gajera, Thanaphong Phongpreecha, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Neurology|April 18, 2020
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFITMarianna Cortese, Kassandra L Munger, Elena H Martínez-Lapiscina, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference ProceedingsChristopher M Perrone, Robert P Lisak, Ethan I Meltzer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 7, 2024
Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluidAleksandra M Wojtas, Eric B Dammer, Qi Guo, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
Proteomic Changes in the Human Cerebrovasculature in Alzheimer's Disease and Related Tauopathies Linked to Peripheral Biomarkers in Plasma and Cerebrospinal FluidAleksandra M Wojtas, Eric B Dammer, Qi Guo, et al.
Nature Communications|August 16, 2023
Whole genome deconvolution unveils Alzheimer's resilient epigenetic signatureEloise Berson, Anjali Sreenivas, Thanaphong Phongpreecha, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapyEva Havrdova, Douglas L Arnold, Jeffrey A Cohen, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialJeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, et al.
Scientific Reports|August 24, 2023
Cross-species comparative analysis of single presynapsesEloïse Berson, Chandresh R Gajera, Thanaphong Phongpreecha, et al.
Pageof 13